Clin Exp Otorhinolaryngol.  2021 Feb;14(1):76-81. 10.21053/ceo.2019.01382.

MicroRNAs Related to Cognitive Impairment After Hearing Loss

Affiliations
  • 1Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, Seoul, Korea
  • 2Department of Otorhinolaryngology, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea
  • 3Department of Biochemistry, Chonnam National University Medical School, Hwasun, Korea
  • 4Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea

Abstract


Objectives
. Our research group has previously demonstrated that hearing loss might be a risk factor for synaptic loss within the hippocampus and impairment of cognition using an animal model of Alzheimer disease. In this study, after inducing hearing loss in a rat model of Alzheimer disease, the associations of various microRNAs (miRNAs) with cognitive impairment were investigated.
Methods
. Rats were divided randomly into two experimental groups: the control group, which underwent sham surgery and subthreshold amyloid-β infusion and the deaf group, which underwent bilateral cochlear ablation and subthreshold amyloid-β infusion. All rats completed several cognitive function assessments 11 weeks after surgery, including the object-in-place task (OPT), the novel object recognition task (NOR), the object location task (OLT), and the Y-maze test. After the rats completed these tests, hippocampus tissue samples were assessed using miRNA microarrays. Candidate miRNAs were selected based on the results and then validated with quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) analyses.
Results
. The deaf group showed considerably lower scores on the OPT, OLT, and Y-maze test than the control group. The microarray analysis revealed that miR-29b-3p, -30e-5p, -153-3p, -376a-3p, -598-3p, -652-5p, and -873-3p were candidate miRNAs, and qRT-PCR showed significantly higher levels of miR-376a-3p and miR-598-3p in the deaf group.
Conclusion
. These results indicate that miR-376a-3p and miR-598-3p were related to cognitive impairment after hearing loss.

Keyword

MicroRNA; Alzheimer Disease; Hearing Loss; Dementia; Hippocampus

Figure

  • Fig. 1. Auditory brainstem response (ABR) threshold results before cochlear ablation and 1, 6, and 11 weeks after surgery. (A) Control group (n=9). (B) Deaf group (n=9). The error bars indicate standard deviation. SPL, sound pressure level.

  • Fig. 2. Results of cognitive tests. The deaf group (n=9) had somewhat lower scores than the control group (n=9) on the object-inplace task (OPT), object location task (OLT), and Y-maze test. NOR, novel object recognition task. The error bars indicate standard error. ***P<0.001 between the groups according to the Mann-Whitney test.

  • Fig. 3. Quantitative reverse transcription-polymerase chain reaction of candidate microRNAs. The relative quantification (RQ) values of miR-376a-3p and miR-598-3p significantly differed between the control (n=6) and deaf (n=6) groups. The error bars indicate standard error. **P<0.01 between the groups according to the MannWhitney test.


Cited by  1 articles

The Use of MicroRNAs for the Early Diagnosis of Dementia in Patients Affected by Hearing Loss
Cha Dong Yeo, Moo Kyun Park
Clin Exp Otorhinolaryngol. 2021;14(1):3-4.    doi: 10.21053/ceo.2021.00017.


Reference

1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; Jan. 18(1):88–106.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011; Mar. 377(9770):1019–31.
Article
3. Cao J, Hou J, Ping J, Cai D. Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegener. 2018; Dec. 13(1):64.
Article
4. Chang M, Kim HJ, Mook-Jung I, Oh SH. Hearing loss as a risk factor for cognitive impairment and loss of synapses in the hippocampus. Behav Brain Res. 2019; Oct. 372:112069.
Article
5. Tran TT, Srivareerat M, Alkadhi KA. Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer’s disease. Neurobiol Dis. 2010; Mar. 37(3):756–63.
Article
6. Hollins SL, Cairns MJ. MicroRNA: small RNA mediators of the brains genomic response to environmental stress. Prog Neurobiol. 2016; Aug. 143:61–81.
Article
7. Campbell K, Booth SA. MicroRNA in neurodegenerative drug discovery: the way forward? Expert Opin Drug Discov. 2015; Jan. 10(1):9–16.
Article
8. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; Nov. 12(12):861–74.
Article
9. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014; Jan. 42(1):609–21.
Article
10. Huang Z, Chen W, Du Y, Guo Q, Mao Y, Zhou X, et al. Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population. J Cancer Res Clin Oncol. 2019; Mar. 145(3):787–96.
Article
11. Ng PC, Chan KY, Yuen TP, Sit T, Lam HS, Leung KT, et al. Plasma miR-1290 is a novel and specific biomarker for early diagnosis of necrotizing enterocolitis-biomarker discovery with prospective cohort evaluation. J Pediatr. 2019; Feb. 205:83–90. e10.
Article
12. Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M, Goldani F, Parizadeh SM, Hassanian SM, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Curr Drug Targets. 2019; 20(11):1129–40.
Article
13. Rezayi M, Farjami Z, Hosseini ZS, Ebrahimi N, Abouzari-Lotf E. MicroRNA-based biosensors for early detection of cancers. Curr Pharm Des. 2018; 24(39):4675–80.
Article
14. Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum microRNAs as biomarkers in hepatitis C: preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma. Int J Mol Sci. 2019; Feb. 20(4):864.
Article
15. Mun SK, Han KH, Baek JT, Ahn SW, Cho HS, Chang MY. Losartan prevents maladaptive auditory-somatosensory plasticity after hearing loss via transforming growth factor-β signaling suppression. Clin Exp Otorhinolaryngol. 2019; Feb. 12(1):33–9.
Article
16. Chang MY, Park S, Choi JJ, Kim YK, Suh MW, Lee JH, et al. MicroRNAs 218a-5p, 219a-5p, and 221-3p regulate vestibular compensation. Sci Rep. 2017; Aug. 7(1):8701.
Article
17. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Burlington (MA): Academic Press;2006.
18. Gallacher J, Ilubaera V, Ben-Shlomo Y, Bayer A, Fish M, Babisch W, et al. Auditory threshold, phonologic demand, and incident dementia. Neurology. 2012; Oct. 79(15):1583–90.
Article
19. Kiely KM, Gopinath B, Mitchell P, Luszcz M, Anstey KJ. Cognitive, health, and sociodemographic predictors of longitudinal decline in hearing acuity among older adults. J Gerontol A Biol Sci Med Sci. 2012; Sep. 67(9):997–1003.
Article
20. Lin FR, Metter EJ, O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and incident dementia. Arch Neurol. 2011; Feb. 68(2):214–20.
Article
21. Lin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, et al. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013; Feb. 173(4):293–9.
Article
22. Brennan S, Keon M, Liu B, Su Z, Saksena NK. Panoramic visualization of circulating microRNAs across neurodegenerative diseases in humans. Mol Neurobiol. 2019; 56(11):7380–407.
Article
23. Boese AS, Saba R, Campbell K, Majer A, Medina S, Burton L, et al. MicroRNA abundance is altered in synaptoneurosomes during prion disease. Mol Cell Neurosci. 2016; Mar. 71:13–24.
Article
24. Huang Q, Wang C, Hou Z, Wang G, Lv J, Wang H, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. Cancer Biomark. 2017; 19(2):137–44.
Article
25. Osei J, Kelly W, Toffolo K, Donahue K, Levy B, Bard J, et al. Thymosin beta 4 induces significant changes in the plasma miRNA profile following severe traumatic brain injury in the rat lateral fluid percussion injury model. Expert Opin Biol Ther. 2018; Jul. 18(sup1):159–64.
Article
Full Text Links
  • CEO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr